Home
About
Services
Partners
Client Portfolio
News
Contact
China’s industrial profits grow at fastest in eight months, but sustained recovery uncertain
December 27, 2019
Oil hits three-month highs as strong U.S. consumer spending underpins growth hopes
December 27, 2019
0
Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
Published by
Muller&Green
at
December 27, 2019
Categories
RSS
Tags
Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month.
Powered by
WPeMatico
Muller&Green
Related posts
June 18, 2020
Chanel warns virus impact will linger on luxury sector
Read more
June 18, 2020
IMF says deeper-than-expected contraction in U.S. economy likely in second quarter
Read more
June 18, 2020
Prudential sells Jackson equity stake to Apollo-backed Athene for $500 million
Read more